Ethical guideposts to clinical trials in oncology by Bernstein, M.
CURRENT ONCOLOGY—VOLUME 13, NUMBER 2
55
ETHICAL GUIDEPOSTS TO CLINICAL TRIALS
ABSTRACT
Clinical research with human subjects is an ethically
challenging task requiring ultimate trust on the part
of patients and ultimate respect for persons on the
part of clinical researchers. The author provides a
simple framework to help researchers ensure the ethi-
cal integrity of a clinical trial in oncology.
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1. INTRODUCTION
In the last few decades, considerable effort has gone
into improving the rigorous assessment of the scien-
tific validity and integrity of the randomized clinical
trial (RCT) 1,2. These steps are based largely on the
invaluable work of the Evidence-Based Medicine
Working Group (EBMWG) 2. A strong initiative is also
under way to standardize how the results of RCTs are
reported 3. However, a pronounced discordance in
attention between the scientific and the ethical di-
mensions of clinical research is apparent and is re-
flected in the emphases of EBMWG and of CONSORT
(Consolidated Standards of Reporting Trials
Group) 2,3. Ethical issues are nonetheless assuming
greater prominence in the conduct, interpretation, and
use of clinical research, particularly as researchers
explore new frontiers that not only invite but com-
mand rigorous ethical scrutiny.
Although most clinical investigators are virtuous
and well-meaning doctors, it is easy for one to un-
knowingly and unwittingly transgress ethical bound-
aries, just as it is easy for a clinical oncologist without
proper training in clinical trial design to use improper
methodology. Some ethical dimensions are obvious
because of common sense, common practice, or com-
mon law—for example, the requirements to submit a
RCT to the relevant institutional research ethics board
(REB) and to obtain informed consent from research
participants. Others dimensions are subtle and nu-
anced—such as the non-financial conflicts of inter-
est experienced by clinical investigators during the
course of clinical research. Furthermore, what con-
stitutes “clinical research” is not always clear. For
example, clinical innovation hovers on the border
between clinical research and the inevitable advance-
ment of the art and science of clinical practice 4.
2. DISCUSSION
Most of the literature on the ethical conduct of re-
search consists of commentary or theoretic analysis,
although a small number of papers have attempted to
formulate usable frameworks 5–7. This article offers
a simple and practical framework that clinical inves-
tigators can use to help assess the bioethical integrity
of a clinical trial in oncology (Table I). The frame-
work is based on the ethical principles of fairness,
respect for persons and autonomy, the available lit-
erature, and the author’s personal experience with
RCTs. All points are presented in the past tense, but it
is implicit that the questions should be asked and
answered before a clinical trial is launched.
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TABLE I Guide to an ethically sound clinical trial
1. Was approval obtained from the research ethics board?
2. Did all patients give fully informed consent?
3. Were eligibility criteria for entry into the study fair and
appropriate?
4. Was the harm:benefit ratio favourable to the patients who
entered the study?
5. How were patients who demanded the experimental therapy
off-study handled?
6. Was the study placebo-controlled, and if so, was the placebo
ethical?
7. Was the effect sought clinically meaningful or just statisti-
cally significant?
8. Were there any conflicts of interest for the study
investigators?
9. Were patients who entered the study paid, and if so, is this
ethical?
10. Did all contributions from co-author justify authorship of
the study publication?56
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2.1 Was REB Approval Obtained?
When a hypothesis is to be tested in a clinical trial,
most clinical investigators know that submitting the
protocol to the institutional REB is an absolute re-
quirement. The job of the REB 8,9 is to make sure that
the research is ethically sound and to suggest ways
to improve it, such as simplifying the consent form.
Most protocols are improved by REB scrutiny, but
these ethics boards are often understaffed, over-
worked, and vulnerable to criticism over how well
and quickly they fulfil their mandates. In fact, the
problem is escalating because the volume of clinical
research at hospitals is continually increasing. It is
not unfair to say that anxiety is growing among many
clinical investigators about how accurately and
promptly their clinical protocol will be assessed by
their REB.
Guidepost 1 All clinical trials should be submitted
to the clinical investigator’s institutional REB. The in-
vestigator should be ready to wait as long as several
months for a response and should be prepared to re-
ceive many suggestions, some of which will be con-
sidered inappropriate or misguided. Investigators
should do their best to comply with all suggestions
or to explain clearly why compliance is impossible.
The language in the consent form should be simple,
but the explanations should be thorough.
2.2 Did All Patents Give Fully Informed Consent?
Informed consent is arguably the most important
ethical dimension of research on human subjects, and
yet it is arguably the most difficult to truly
achieve 10,11. Fully informed consent has three fun-
damental components 12:
• Adequate disclosure of information
• Full patient capacity to comprehend the information
• Voluntariness or freedom of the patient to make
a decision
For a RCT to be justified, a state of clinical uncer-
tainty about the relative merits of a trial’s arms—that
is, the groups or methods being compared—must
exist. This requirement alone is a difficult concept
for most patients to grasp, and it is a sufficiently nu-
anced and sophisticated concept that even research-
ers exhibit inconsistency in grasping this very
fundamental premise behind clinical research 13.
A priori, a patient is entirely unable to know in ad-
vance whether participation in a study might be of
personal benefit. The clinical investigator must be
completely honest about presenting the experimen-
tal nature of the treatment being offered and must
avoid propagating the widespread therapeutic mis-
conception in which the patient believes that an offer
of an opportunity to access a beneficial therapy is
being extended 14,15.
Furthermore, clinical investigators cannot possi-
bly predict every foreseeable complication of an ex-
perimental therapy, because previously unknown and
unencountered complications can arise in the course
of clinical research. This was the case in the first RCT
of high-activity interstitial brachytherapy for de novo
glioblastoma multiforme: two patients developed
devastating strokes from radiation injury to the middle
cerebral artery 16.
Full capacity is arguably impaired in most pa-
tients being confronted with the daunting task of try-
ing to digest all the information concerning a complex
trial and making a decision that may have an impact
on their quality of life or very survival. Voluntariness
may also be adversely affected by a myriad of forces.
In the final analysis, the most important component
in clinical decision-making and the consent process
for many patients may simply be their trust in the
clinical investigator 17.
Guidepost 2 Clinical investigators must do their hon-
est best to explain everything a reasonable person
would want or need to know before entering a clini-
cal trial. They should be honest about the unknown
benefits of the therapy being studied. Simple language
should be used in conversation with patents, and the
investigator must be prepared to have more than one
meeting with the patient if necessary. The investiga-
tors must be ever vigilant in maintaining complete
respect for research subjects and in ensuring that
every subject’s autonomy and dignity are preserved
at all times.
2.3 Were the Eligibility Criteria for Entry into the
Study Fair and Appropriate?
To increase internal validity, inclusion and exclusion
criteria for clinical trials are made relatively stringent.
This stringency is important, because the expenditure
of human and fiscal resources required to run a clini-
cal trial must be justified by the strong likelihood that
scientifically valid and usable information will result.
The trade-off may be reduced applicability of the re-
sults—that is, the results may be applicable to only a
small subset of patients with the disease under study.
Clinical investigators must make sure, as best as
possible, that access to a clinical trial is equitable and
fair to all potential study subjects. Some examples of
unfair access are egregious—for example, exclusion
of vulnerable populations based on the disease under
study, race, or type of health insurance 18. More com-
mon and everyday examples are “near-misses,” when
patients fall just short of attaining eligibility for a trial.
For example, how might a 67-year-old woman with
breast cancer feel if a new trial of chemotherapy were
to exclude her because the criterion for age was
65 years and under?
Guidepost 3 Clinical trials must be designed to pro-
vide the best possible opportunity for a definitiveCURRENT ONCOLOGY—VOLUME 13, NUMBER 2
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result without making the inclusion criteria narrower
than absolutely necessary. But clinical investigators
must be sensitive to patients who feel disadvantaged
by ineligibility for entry and must be prepared to pro-
vide information to mitigate their feeling of being
“left out.”
2.4 Was the Harm:Benefit Ratio Favourable to the
Patients Who Entered the Study?
Before any clinical trial, detailed analysis of the po-
tential harms of the experimental arm in particular
must be weighed, and all research in animal studies
and in phase I and II human studies must be consid-
ered. The evidence must point in the direction of the
experimental therapy having a strong—or, at mini-
mum, a reasonable—chance of providing therapeu-
tic benefit to patients. The uniformly dismal prognosis
of a disease (for example, recurrent glioblastoma
multiforme) should not be used to justify a study of
an experimental treatment with an unreasonably high
risk.
Complications, quality of life, and survival in each
arm must be monitored on an ongoing basis, with the
proviso that the study can be stopped if complica-
tions are excessive or if the outcome in either arm
appears incontrovertibly worse or better than in the
other 19. An independent safety and monitoring com-
mittee, well-versed in the possible pitfalls of inaccu-
rate assessment of results, particularly early in a trial,
should oversee the RCT 19,20.
Guidepost 4 No matter how exciting an experimen-
tal therapy may appear in animal or early clinical ob-
servations, clinical investigators must strongly
consider all foreseeable harms and be watchful for
unanticipated ones. An independent monitoring com-
mittee should be sought to oversee the RCT, with the
power to stop the trial under certain circumstances.
2.5 How Were Patients Who Demanded the
Experimental Therapy Off-Study Handled?
As patients become more informed and self-advo-
cating, many hear about an experimental therapy and
feel strongly enough about it to demand the treat-
ment without wishing to risk randomization that gives
them only a 50% chance of receiving it. How should
such situations be handled?
Little has been written on this difficult issue 21,
but as a starting point, providing the new treatment
on demand must be considered intrinsically unfair to
those who agreed to randomization. It could even bias
the study results, because unknown factors associ-
ated with more-vocal patients might correlate with
better or worse outcomes. Anything that could bias
the result of a RCT must be considered inherently un-
acceptable, because bad science is bad ethics. If an-
other centre is known to provide the experimental
therapy off-study, the investigator should provide the
patient with that information and assist with a refer-
ral for the therapy if the patient desires it.
Guidepost 5 When a patient demands an experimen-
tal therapy off-study, the clinical investigator should
not comply. The investigator should explain the rea-
sons to the patient and should provide any available
information on securing the treatment elsewhere.
2.6 Was the Study Placebo-Controlled, and If So,
Was the Placebo Ethical?
Much has been written about the ethics of placebos
in clinical investigation 22–24. Obvious ethical issues
aside, the well-recognized placebo effect may con-
taminate the scientific results of a clinical trial 25. Use
of placebos may expose participants to levels of risk
that are unacceptable even if informed consent has
been given. Placebos also produce an inherent level
of deception, in spite of informed consent having been
obtained. Some authors argue that placebos are ac-
ceptable under certain circumstances 23; others feel
that placebos are generally unethical 22,24.
Placebos in surgical oncology trials (that is, sham
surgery) must be rare, but precedents exist for inva-
sive placebo-controlled arms in other surgical trials.
A recent example involved placement, on the pla-
cebo arm, of an intraventricular catheter into the
brains of patients with Parkinson disease 26. A recent
survey of clinical researchers overwhelmingly en-
dorsed the scientific value of sham-surgery controls,
but only a minority of respondents (22%) believed
that an invasive sham control is ethically justified 27.
The use of placebos in medical oncology trials is
common 28–30, and while not exposing subjects to risk,
such a strategy exposes those patients to deception
in spite of informed consent.
Guidepost 6 Any placebo in a RCT that tips the
harm:benefit ratio unfavourably should be considered
unethical. This conclusion would obtain for all imag-
inable surgical placebos and perhaps for fewer medi-
cal placebos. Benefit that accrues to the scientific
validity of a study cannot come at any foreseeable—
and therefore avoidable—risk to participating patients.
2.7 Was the Effect Being Sought Clinically
Meaningful or Just Statistically Significant?
Clinically relevant outcomes are a desirable subset
of study outcomes that are also statistically signifi-
cant. Traditionally, power calculations have been
derived on statistical grounds; they must be rigor-
ously performed to avoid the waste of human and
fiscal resources associated with underpowered stud-
ies 31. Literature on minimally important clinical dif-
ferences, which patients find relevant when asked, is
also emerging 32. Indications are that a mismatch may
exist between patients’ expectations of treatment and
actual outcomes from clinical interventions 33. A null58
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study provides an ethically acceptable result because
it may obviate unnecessary human costs (that is, com-
plications) and fiscal costs by recommending discon-
tinuation of a fruitless experimental therapy. This was
the case with interstitial brachytherapy for malignant
gliomas mentioned earlier 34.
Besides quantitative outcomes such as prolonga-
tion of survival, time to progression, and 2-year sur-
vival (for example), qualitative outcomes such as
quality of life are assuming greater importance in
clinical trials, especially in oncology 35–37. Many
would argue that no RCT should be conceived or ex-
ecuted without measurement of quality of life as a
primary outcome measure.
Guidepost 7 Power calculations for a RCT must be
rigorously performed, and a trial should be designed
to discover differences that are clinically relevant to
patients. If such information is unavailable, the clini-
cal investigator should try to estimate what reason-
able people would consider a worthwhile study
outcome. Quality-of-life measurement should be built
into every RCT in oncology.
2.8 Were There Any Conflicts of Interest for the
Study Investigators?
Financial conflicts of interest (COIs) at an individual
or institutional level have obvious potential as sources
of bias or coercion that can influence RCTs. Because
such conflicts are becoming well-recognized, nowa-
days all such potential COIs have to be transparently
communicated to peers 38,39. But should patients be
made aware of COIs? Most investigators avoid con-
fronting this issue. Yet a financial COI could affect a
clinical investigator’s aggressiveness in recruiting
patients to a RCT (for example), and in the extreme
scenario, could alter judgments about who is an ap-
propriate candidate for a study.
Non-financial COIs may be quite subtle and may
exist for many reasons. For example, secret belief by
the clinical investigator that the experimental therapy
works can contribute to a more aggressive stance in
recruiting patients, out of a desire to help them. Al-
ternatively or in tandem, aggressive recruitment trans-
lates into quicker completion and earlier publication
of the study, with resultant career advancement.
Clinical investigators must become aware of such
influences. Some purists believe that the clinical in-
vestigator in a RCT should not be the clinician actu-
ally caring for the patient 40. Others believe that, with
vigilance to avoid subtle coercion or taking advan-
tage of patients’ profound trust, care by the investi-
gator is ethically acceptable 41. The situation of care
by the investigator is likely necessary, because it is
clinicians interested in exploring new therapies for
their patients who generate local interest in the con-
duct of clinical trials. Without the integral involve-
ment of these individuals, the clinical research study
would likely not be initiated or attain success.
Guidepost 8 Clinical investigators must be aware of
financial and non-financial forces that, through their
powerful influence, can produce tension between the
role of investigator and the role of healer. Clinical in-
vestigators must actively resist any temptation to allow
these forces to unduly influence their behaviour in the
investigator role. Every financial COI must be disclosed.
2.9 Were Patients Who Entered the Study Paid, and
If So, Is This Ethical?
Although reimbursement is a relatively uncommon
practice in oncology RCTs, participants in some stud-
ies are reimbursed at minimum for expenses such as
travel and parking associated with the extra clinic
visits entailed by the trial. In some trials, however,
participants are reimbursed above and beyond the real
costs accrued 42,43. Any payment can be seen as a form
of enticement or undue influence for a prospective
subject to join a RCT and therefore must be consid-
ered an ethically undesirable practice 44. Payment
negatively influences the voluntariness component
of informed consent discussed earlier.
Guidepost 9 Clinical investigators should not allow
research subjects to be paid for participation in a RCT.
2.10 Did All Co-authors’ Contributions Justify
Authorship in the Study Publication?
Fabricated data, spurious authorship, and duplicate
publication continue to be unethical practices in the
publication of biomedical research 45,46. The only
exception for multiple identical publications is posi-
tion papers such as the statement on clinical trial reg-
istration by De Angelis and colleagues 47, which
appears in about thirty different journals. And many
would question the ethics even of this practice.
Currently, written justification of author contri-
butions is required by many peer-reviewed journals.
Every author listed must have earned credit for the
manuscript by developing the study concept and de-
sign, by generating data, by writing the paper, by
doing substantive editorial work, or by undertaking
some combination of these components. Individuals
who have made meaningful contributions must not
be omitted. Attention must also be given to the order
of authorship, which should be fairly assigned by
equitable consensus among the co-authors, accord-
ing to their relative contributions.
Guidepost 10 Clinical investigators must make sure
that authorship of the results of a trial honestly and
fairly reflects the work of all who contributed and
only of those who did. Journals should probably re-
quest justification of authorship.
3. CONCLUSION
A simple framework that addresses essential elements
of the bioethical integrity of a clinical trial in oncologyCURRENT ONCOLOGY—VOLUME 13, NUMBER 2
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has been presented here. It would be presumptuous to
suggest that this framework is exhaustive or authori-
tative, but perhaps it can act as a springboard for in-
vestigators considering the ethical dimensions of their
work. Also, this framework is subjective and largely
reflects the beliefs of the author. No class I evidence is
available to inform us about the issues raised—just
attention to basic ethical principles and theories and
thoughts from other thinkers in these areas.
Good clinical research is ultimately ethically de-
sirable because it represents an attempt by investiga-
tors always to strive to improve outcomes for their
patients. However, good intentions are not sufficient.
Good bioethical conduct of clinical research is not
widely taught in our undergraduate or graduate cur-
ricula—and even if it were, the face of research is
changing so rapidly that new ethical dilemmas arise
continually to challenge clinical investigators.
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